Tokai Pharmaceuticals Inc Share Price Nasdaq
Equities
US88907J1079
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | 25M 1.97B | Capitalization | 58.06M 4.58B |
---|---|---|---|---|---|
Net income 2024 * | -47M -3.71B | Net income 2025 * | -44M -3.47B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.32 x |
P/E ratio 2024 * |
-2.07
x | P/E ratio 2025 * |
-3.24
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.45% |
Latest transcript on Tokai Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 30/04/20 | |
Paul Little
DFI | Director of Finance/CFO | 60 | 14/03/21 |
Steven N. Perrin
PSD | President | 59 | 13/09/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Keith Katkin
CHM | Chairman | 52 | 30/04/17 |
Walter C. Ogier
BRD | Director/Board Member | 67 | 13/09/20 |
John S. McBride
BRD | Director/Board Member | 72 | 30/04/17 |
1st Jan change | Capi. | |
---|---|---|
+7.83% | 111B | |
+11.18% | 106B | |
-12.21% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.77% | 16.81B | |
+38.51% | 12.54B | |
-24.46% | 8.09B |